Du är här

2016-02-24

MPI: Registration of capital increase completed

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA

Hoersholm; February 24, 2016 - Medical Prognosis Institute A/S (MPI.CO)
(Denmark og Phoenix, AZ, USA) announced today that registration of capital
increase is completed.

With reference to company announcement published on February 19th2016 we are
pleased to announce that the capital increase of 64,345 new shares with a
nominal value of DKK 1 each was registered with the Danish Business Authority
today.

Following registration of the 64,345 new shares with a nominal value of DKK 1
each, the nominal value of the share capital of Medical Prognosis Institute
A/S amounts to DKK 1,164,115 divided into 1,164,115 shares with a nominal
value of DKK 1 each.

Each share of nominally DKK 1 carries one vote at general meetings in the
company.

The new shares is to be traded on First North Copenhagen under the same ISIN
code as the company's existing shares with expected first day of trading on
March 1st2016.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop
tumor-derived gene signatures that may predict which cancer patients are
highly likely responders to a given anticancer product. The DRP(TM) has been
tested in 37 trials, where 29 trials showed that drug-specific DRP(TM)
Biomarkers could predict which patients had a positive effect of the
treatment. The DRP(TM) platform has also been externally validated and
published in collaboration with leading statisticians at the MD Anderson
Cancer Center. The DRP(TM) method can be used to design the Clinical
Development Plan, i.e. to select which indications are relevant for a given
anticancer drug. Further to and in addition to this, individual patients'
gene patterns can be analyzed as part of a screening procedure for a clinical
trial to ensure inclusion of those patients who have a high likelihood of
response to the drug. This DRP(TM) method builds on the comparison of
sensitive and resistant human cancer cell lines including genomic information
from cell lines combined with clinical tumor biology and clinical correlates
in a systems biology network. MicroRNA is used on certain products whereas
the messenger RNA is more broadly useable and more validated. The DRP(TM)
platform can be used in all cancer types and has been patented for more than
60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with
cancer drug developers to apply its DRP(TM) diagnostic platform to streamline
and de-risk clinical trials and drug development via biomarker optimization,
patient stratification, and development of companion diagnostics.

For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
e-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 22

Certified Advisor:

Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup,
Denmark

Registration of capital increase completed
http://hugin.info/158657/R/1989020/730437.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire

HUG#1989020

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.